HealingFDA ApprovedFDA Approved

Ziconotide

Also known as Prialt, SNX-111

A synthetic cone snail venom peptide for severe chronic pain. The first intrathecal non-opioid analgesic FDA approved.

FDA Approved - Severe chronic pain

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

Via intrathecal pump (individualized)

Frequency

Continuous intrathecal infusion

Duration

Chronic use via intrathecal pump

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: Via intrathecal pump (individualized) via Intrathecal infusion only, Continuous intrathecal infusion. Dose range: Individualized intrathecal dosing. Duration: Chronic use via intrathecal pump.

Timing & Administration

Administer via Intrathecal infusion only. Frequency: Continuous intrathecal infusion.

Mechanism of Action

Blocks N-type voltage-gated calcium channels (Cav2.2) in the spinal cord. Prevents neurotransmitter release from pain-signaling neurons, providing analgesia without opioid receptor involvement.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - Severe chronic pain.

Side Effects & Safety

Important Warnings

  • BLACK BOX WARNING: Severe psychiatric symptoms
Dizziness (40%)
nausea
confusion
hallucinations
depression
suicidal ideation
memory impairment

References

No references available.